OncoMatch/Clinical Trials/NCT07047586
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
Is NCT07047586 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Lenvatinib for hepatocellular carcinoma (hcc).
Treatment: Tislelizumab · Lenvatinib — To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy — combination with bevacizumab
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC
Must have received: anti-PD-L1 therapy — combination with bevacizumab
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC
Must have received: VEGF inhibitor (bevacizumab) — combination with anti-PD-1/PD-L1
Disease progression following prior anti-PD1/PD-L1 plus bevacizumab combination treatment for HCC
Lab requirements
Blood counts
absolute neutrophil count ≥ 1,500/L, platelets ≥60 x10^3/L
Kidney function
Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula)
Liver function
Child-Pugh scores 5-7; Total bilirubin ≤ 3x upper normal limit; AST/ALT ≤ 5x ULN; INR ≤1.25; Albumin ≥ 31 g/dL
Adequate blood count, liver-enzymes, and renal function: absolute neutrophil count ≥ 1,500/L, platelets ≥60 x103/L; Total bilirubin ≤ 3x upper normal limit; Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) ≤ 5 x upper normal limit (ULN); International normalized ratio (INR) ≤1.25; Albumin ≥ 31 g/dL; Serum Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 30 mL/min (if using the Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify